Syndax Pharmaceuticals R&D head sells 65,515 shares for $1.2M under 10b5-1 plan as stock falls 22.3% in 90 days
Nicholas A.J. Botwood, Head of R&D and CMO at Syndax, executed 2 separate sales totaling 65,515 shares for $1,183,642.90 at blended average price $18.07 on 2026-06-11 and 2026-06-12. This sale represents a 51.8% reduction in his pre-transaction holdings of 126,400 shares, leaving him with 60,885 shares post-transaction. The sales were scheduled under a 10b5-1 trading plan rather than discretionary decisions. Against the current price of $18.25, the stock is down 22.3% over the prior 90 days and down 28.7% from its 52-week high of $25.59. The company remains unprofitable with net income of $-42,673,000.00 in the latest quarter, despite significant revenue growth of 627.8% year-over-year to $64,864,000.00. His prior purchase at this same ticker on 2025-05-16 showed 90-day returns of 63.8%, but his current planned sales occur amid material stock weakness and ongoing operational losses.